Clinical trial designs for testing biomarker-based personalized therapies

Clinical Trials

Volumn 9, Issue 2, 2012, Pages 141-154

  Lai, Tze Leung ^a   Lavori, Philip W ^a   Shih, Mei Chiung I ^a,b   Sikic, Branimir I ^c  

^a STANFORD UNIVERSITY   (United States)

^b VA Cooperative Studies Program   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; BIOLOGICAL MARKER; DOCETAXEL; DOXORUBICIN; ERLOTINIB; SORAFENIB; TOPOTECAN; VANDETANIB;

ADAPTIVE RANDOMIZATION; ARTICLE; BAYESIAN LEARNING; BIOMARKER GUIDED STRATEGY; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; GENE EXPRESSION; GENERALIZED LIKELIHOOD RATIO; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM LIKELIHOOD METHOD; NULL HYPOTHESIS; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT CARE; PERSONALIZED MEDICINE; PHYSICIAN; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; SAMPLE SIZE; SIMULATION; STRATEGIC PLANNING; STUDY DESIGN; TREATMENT PLANNING; TREATMENT RESPONSE; VALIDATION PROCESS;

BAYES THEOREM; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, STATISTICAL; OVARIAN NEOPLASMS; PLATINUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84861814820     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512437252     Document Type: Article

References (38)

1. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res. 2004 ; 10: 6759-63
2. Simon R. Development and validation of biomarker classifiers for treatment selection. J Stat Plan Infer. 2008 ; 138: 308-20
3. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: Design issues. J Natl Cancer I. 2010 ; 102: 152-60
4. Cree IA, Kurbacher CM, Lamont A, et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anti-Cancer Drug. 2007 ; 18: 1093-101
5. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Pers Med. 2010 ; 7: 33-47
6. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: Lessons from real trials. Clin Trials. 2010 ; 7: 567-73
7. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer-A step toward personalized medicine. Clin Trials. 2008 ; 5: 181-93
8. Lee JJ, Gu X, Liu S. Bayesian adaptive randomization designs for targeted agent development. Clin Trials. 2010 ; 7: 584-96
9. Kim ES, Herbst RS, Wistuba II. The BATTLE trial: Personalizing therapy for lung cancer. et al Cancer Disc. 2011 ; 1: 44-51
10. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 ; 86: 97-100
11. Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 ; 95: 624-31
12. Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A. New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents. Crit Rev Oncol Hemat. 2008 ; 67: 103-12
13. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 ; 19: 3312-22
14. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol Oncol. 2004 ; 93: 98-106
15. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2003 ; 88: 130-35
16. Faggad A, Darb-Esfahani S, Wirtz R, et al. Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: Correlation with clinicopathological factors and prognosis. Modern Pathol. 2009 ; 22: 579-88
17. Ferrandina G, Petrillo M, Carbone A, et al. Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients. Brit J Cancer. 2008 ; 98: 1910-15
18. Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000 ; 20: 1061-67
19. Khalifa MA, Abdoh AA, Mannel RS, et al. P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. Int J Gynecol Pathol. 1997 ; 16: 69-75
20. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol. 2008 ; 26: 2690-98
21. Codegoni AM, Castagna S, Mangioni C, et al. DNA-topoisomerase I activity and content in epithelial ovarian cancer. Ann Oncol. 1998 ; 9: 313-19
22. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskel. 2003 ; 56: 45-56
23. Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, Bronstein IB. Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol Pathol. 1997 ; 50: 247-53
24. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997 ; 100: 1282-93
25. Koshiyama M, Fujii H, Kinezaki M, Yoshida M. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Res. 2001 ; 21: 905-10
26. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005 ; 11: 298-305
27. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003 ; 14: 4376-86
28. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008 ; 14: 5198-208
29. Liu A, Liu C, Li Q, Yu KF, Yuan VW. A threshold sample-enrichment approach in a clinical trial with heterogenous subpopulations. Clin Trials. 2010 ; 7: 537-45
30. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 ; 10: 1-10
31. Lai TL, Shih MC. Power, sample size and adaptation considerations in the design of group sequential clinical trials. Biometrika. 2004 ; 91: 507-28
32. Hu F, Rosenberger WF. The Theory of Response-Adaptive Randomization in Clinical Trials. Wiley, New York: ; 2006 :
33. Reid N. Saddlepoint methods and statistical inference. Stat Sci. 1988 ; 23: 213-27
34. Ledford H. Clinical drug tests adapted for speed. Nature. 2010 1258 ; 464 :
35. Gu X, Lee J. A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol. 2010 ; 10: 48
36. Korn EL, Freidlin B. Outcome-adaptive randomization: Is it useful?. J Clin Oncol. 2011 ; 29: 771-76
37. Morgan CC, Coad SD. A comparison of adaptive allocation rules for group-sequential binary response clinical trials. Stat Med. 2007 ; 26: 1937-54
38. Berry DA. Adaptive clinical trials: The promise and the caution. J Clin Oncol. 2010 ; 29: 606-09